Open-label, multi center PET/CT (positron emission tomography/computed tomography) study for investigation of safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 following a single intravenous administration of 140 MBq (corresponding to ≤ 40µg mass dose) in patients with primary prostate cancer

Trial Profile

Open-label, multi center PET/CT (positron emission tomography/computed tomography) study for investigation of safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 following a single intravenous administration of 140 MBq (corresponding to ≤ 40µg mass dose) in patients with primary prostate cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Gallium 68 RM2 (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Sponsors Piramal Imaging
  • Most Recent Events

    • 20 Mar 2017 Status changed from recruiting to discontinued.
    • 11 Feb 2017 This trial has been discontinued in Austria (end date: 16 Jan 2017).
    • 27 Jan 2017 This trial has been discontinued in Finland (end date: 16 Jan 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top